Skandigen intends to raise $4 million:
This article was originally published in Clinica
Swedish biotechnology company Skandigen intends to raise SKr 27 million ($4 million) to fund development work of its various subsidiaries, most notably UK-based Fermentech (see Clinica No 666, p 14). Skandigen will issue 1.1 million new stock at a price of SKr 25 per share. The offer closed on August 18th.
You may also be interested in...
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.
Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex
T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.